Hormonal status affects plasma exposure of tamoxifen and its main metabolites in tamoxifen-treated breast cancer patients

• Hauptverfasser: João Paulo Bianchi Ximenez (Verfasst von), Jurandyr Moreira de Andrade (Verfasst von), Maria Paula Marques (Verfasst von), Eduardo Barbosa Coelho (Verfasst von), Guilherme Suarez-Kurtz (Verfasst von), Vera Lucia Lanchote (Verfasst von)
• Format: Buch
• Veröffentlicht: BMC, 2019-12-01T00:00:00Z.
• Schlagworte: article
• Online-Zugang: Connect to this object online.

Abstract Background Tamoxifen is considered a prodrug of its active metabolite endoxifen, which is dependent on the CYP2D6 and CYP3A enzymes. Tamoxifen pharmacokinetic variability influences endoxifen exposure and, consequently, its clinical outcome. This study investigated the impact of hormonal st...